Comparative Pharmacology
Head-to-head clinical analysis: AFIRMELLE versus NORCEPT E 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFIRMELLE versus NORCEPT E 1 35 21.
AFIRMELLE vs NORCEPT-E 1/35 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13-27 hours), consistent with once-daily dosing; norethindrone: terminal half-life approximately 7.6 hours (range 5-12 hours), permitting steady-state within 5 days.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Renal: 50-60% as metabolites (primarily ethinyl estradiol glucuronide and norethindrone metabolites); fecal: 20-30% via biliary elimination; unchanged drug: <5%.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive